Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013421 (dystonia)
 8,418 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Few investigations have examined sleep in cervical dystonia (CD) patients. We assessed 43 consecutive CD patients, 19 patients with other focal movement disorders, and 49 healthy, age- and gender-matched controls for the presence of excessive daytime sleepiness (as measured by the Epworth Sleepiness Scale, ESS). All patients were receiving botulinum toxin. We found that a higher percentage of CD patients had abnormal ESS scores of >11 than did either of the two control groups (21% vs. 0% vs. 4%, p < 0.05 for each pairwise comparison with the CD group). Use of anticholinergic medications accounted for some but not all of this increase in sleepiness in the CD group. Age, gender, race, scores on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) or its subscores (severity, disability, and pain), and other common medication use (benzodiazepines, antidepressants) were not associated with increased ESS scores. This preliminary finding of excessive daytime sleepiness in a substantial portion of CD patients suggests that further investigation into disordered sleep in CD is warranted.
 ...
PMID:Excessive daytime sleepiness in cervical dystonia. 1944 65

Disorders of initiation and maintenance of sleep (DIMS), excessive daytime sleepiness (EDS) are common and clinically significant in patients with Parkinson's disease (PD). The aim of the study was the evaluation of the effects of the dopamine agonist pramipexole on DIMS and EDS in PD. Sixty-seven patients with PD (mean age 63.2+/-9.9 years old, mean illness duration 6.5+/-4.2 years) were enrolled in the study. Forty patients received pramipexole as add-on to the other antiparkinsonian medications in mean daily dosage 2.64+/-0.6 mg. Clinical symptoms were assessed using the UPDRS, the PDSS, the PSO, the ESS, the Beck Depression Inventory (BDI), the Spielberger's State Anxiety Inventory, the SCOPA-Cog, the PDQ-39. The most common sleep complaints were sleep fragmentation and early awakening. DIMS, EDS were the main factors which negatively influenced the overall quality of sleep. The administration of pramipexole significantly improved the overall quality of sleep, decreased sleep initiation difficulties and sleep fragmentation, night and early morning dystonia, early morning tremor; restlessness, troublesome sensations in extremities, nocturia. We speculate that the effects of therapy on DIMS are caused by the decrease of nocturnal PD motor (hypokinesia, dystonia, tremor) and nonmotor (nocturia, sensor disturbances) symptoms; 15% of patients had moderate ESS in the early treatment period.
 ...
PMID:[Effects of the dopamine agonist mirapex (pramipexole) therapy on sleep disorders in Parkinson's disease]. 2051 25